Advertisement

Topics

Compugen Company Profile

10:01 EDT 22nd October 2018 | BioPortfolio

Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based on a decade long focus on in silico (by computer) prediction and selection of therapeutic and diagnostic product candidates utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. Compugen’s growing number of collaborations with major pharmaceutical and diagnostic companies cover both (i) the licensing of product candidates discovered by Compugen during the validation of its discovery platforms and in its internal research, and (ii) “discovery on demand” agreements where existing or new Compugen discovery platforms are utilized to predict and select product candidates as required by our partner. In 2002, Compugen established an affiliate, Evogene Ltd. (TASE: EVGN.TA) to utilize certain of the Company’s in silico predictive discovery capabilities in agricultural biotechnology. Compugen has been publicly traded on Nasdaq (NASDAQ: CGEN) since August 2000 and on the Tel Aviv Stock Exchange since January 2002.

Location

72 Pinchas Rosen St.
Tel Aviv
69512
Israel

Contact

Phone: +972-3-765-8585
Fax: +972-3-765-8555
Email: info@cgen.com


News Articles [54 Associated News Articles listed on BioPortfolio]

BMS invests $12m in cancer immunotherapy tie-up with Compugen

Bristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could boost the effectiveness of its blockbuster cancer immunotherapy Opdivo. BMS said i...

Bristol-Myers, Compugen To Jointly Evaluate Combination Of COM701 With Opdivo

NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and Compugen (CGEN) announced a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investiga...

Compugen inks I-O deal worth over $210 million with AZ unit

Compugen has entered into an exclusive license agreement with MedImmune.

Compugen Ltd. (CGEN) Compugen and Bristol-Myers Squibb Clinical Collaboration and Equity Investment Conference Call (Transcript)

Compugen earns $7.8m payment from Bayer

The continued development of cancer drug BAY 1905254 is a major boost for Compugen's ability to successfully identify new mechanisms for treatments using its big data systems.

BMS to invest in, collaborate with Compugen

Bristol-Myers Squibb and Israel-based Compugen said they will collaborate in clinical trials for patients with advanced solid tumors.

AZ signs up for access to Compugen’s pipeline

AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.

BMS invests $12m in Compugen for tumor collaboration

The companies have entered into a clinical trial collaboration to evaluate Compugen’s COM701 with BMS's PD-1 immune checkpoint inhibitor Opdivo, in patients with advanced solid tumors.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [5 Associated Companies listed on BioPortfolio]

Compugen Ltd.

Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are b...

Compugen

Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based...

Compugen Ltd. Compugen Ltd.

Compugen is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology ...

Neviah Genomics

Neviah Genomics was jointly established in 2012 by Merck Serono, the biopharmaceutical business of Merck, and Compugen Ltd. The company operates out of the MS Ventures’ Israe...

BioLineRx Ltd. and Compugen Ltd.

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over curr...

More Information about "Compugen" on BioPortfolio

We have published hundreds of Compugen news stories on BioPortfolio along with dozens of Compugen Clinical Trials and PubMed Articles about Compugen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Compugen Companies in our database. You can also find out about relevant Compugen Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record